Consensus is for FY25 revenue $1.35B. The Company maintains guidance for U.S. Thrombectomy growth of 20% to 21% compared to 2024 levels. The Company also maintains guidance for both gross margin and operating margin for FY25.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra reports Q2 non-GAAP EPS 86c, consensus 82c
- PEN Earnings this Week: How Will it Perform?
- Penumbra’s Strategic Growth Potential Highlighted by Upcoming Thunderbolt System Launch and Innovation in Aspiration Technology
- Penumbra price target lowered to $285 from $320 at Citi
- Penumbra announces FDA approval, launch of Ruby XL System